Android Apple

Intra-Cellular bolsters Caplyta data with another Phase III win

By Yahoo! Finance   |   1 month ago
Intra-Cellular bolsters Caplyta data with another Phase III win

Intra-Cellular Therapeutics reports positive results from a Phase III trial of Caplyta for preventing relapse in schizophrenia patients. The study showed a 63% reduction in relapse risk with Caplyta compared to placebo.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.